{"pmid":32232977,"title":"Response to \"Comments on 'Zhang et al.: Clinical trial analysis of 2019-nCoV therapy registered in China '\".","text":["Response to \"Comments on 'Zhang et al.: Clinical trial analysis of 2019-nCoV therapy registered in China '\".","We thank Dr. Yang and colleagues for their attention to our article(1,2) . And we appreciate their meaningful suggestions, which we highly agree with. With the purpose of letting the public know the overall situation of the clinical trials of new coronary pneumonia in China as soon as possible, we completed the data collection and brief analysis in a very short time. This article is protected by copyright. All rights reserved.","J Med Virol","Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian","32232977"],"abstract":["We thank Dr. Yang and colleagues for their attention to our article(1,2) . And we appreciate their meaningful suggestions, which we highly agree with. With the purpose of letting the public know the overall situation of the clinical trials of new coronary pneumonia in China as soon as possible, we completed the data collection and brief analysis in a very short time. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232977","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25803","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1662899337781313537,"score":7.3910046,"similar":[{"pmid":32108352,"title":"Clinical trial analysis of 2019-nCoV therapy registered in China.","text":["Clinical trial analysis of 2019-nCoV therapy registered in China.","So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.","J Med Virol","Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian","32108352"],"abstract":["So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period."],"journal":"J Med Virol","authors":["Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108352","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25733","keywords":["China","clinical trial","new coronavirus pneumonia","new drugs"],"source":"PubMed","locations":["China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662334544207937536,"score":139.00993},{"pmid":32227489,"title":"Concerns regarding calculation of fatality rate of Chinese samples in COVID-19 meta-analysis.","text":["Concerns regarding calculation of fatality rate of Chinese samples in COVID-19 meta-analysis.","I read with interest the meta-analysis of patient clinical characteristics and fatality rates in COVID-19 from Chinese samples by Li and colleagues(1) . I was surprised by the fatality rate of 7% which is much than higher than the value of 1.4% reported in a large study of Chinese patients by Guan et al (2020)(2) . This article is protected by copyright. All rights reserved.","J Med Virol","Kempton, Matthew","32227489"],"abstract":["I read with interest the meta-analysis of patient clinical characteristics and fatality rates in COVID-19 from Chinese samples by Li and colleagues(1) . I was surprised by the fatality rate of 7% which is much than higher than the value of 1.4% reported in a large study of Chinese patients by Guan et al (2020)(2) . This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Kempton, Matthew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227489","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25799","source":"PubMed","locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1662819280328065024,"score":115.83933},{"pmid":32222993,"title":"GENOMIC CHARACTERISATION AND PHYLOGENETIC ANALYSIS OF SARS-COV-2 IN ITALY.","text":["GENOMIC CHARACTERISATION AND PHYLOGENETIC ANALYSIS OF SARS-COV-2 IN ITALY.","This report describes the isolation, molecular characterisation and phylogenetic analysis of the first three complete genomes of SARS-CoV-2 isolated from three patients involved in the first outbreak of COVID-19 in Lombardy, Italy. Early molecular epidemiological tracing suggests that SARS-CoV-2 was present in Italy weeks before the first reported cases of infection. This article is protected by copyright. All rights reserved.","J Med Virol","Zehender, Gianguglielmo","Lai, Alessia","Bergna, Annalisa","Meroni, Luca","Riva, Agostino","Balotta, Claudia","Tarkowski, Maciej","Gabrieli, Arianna","Bernacchia, Dario","Rusconi, Stefano","Rizzardini, Giuliano","Antinori, Spinello","Galli, Massimo","32222993"],"abstract":["This report describes the isolation, molecular characterisation and phylogenetic analysis of the first three complete genomes of SARS-CoV-2 isolated from three patients involved in the first outbreak of COVID-19 in Lombardy, Italy. Early molecular epidemiological tracing suggests that SARS-CoV-2 was present in Italy weeks before the first reported cases of infection. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zehender, Gianguglielmo","Lai, Alessia","Bergna, Annalisa","Meroni, Luca","Riva, Agostino","Balotta, Claudia","Tarkowski, Maciej","Gabrieli, Arianna","Bernacchia, Dario","Rusconi, Stefano","Rizzardini, Giuliano","Antinori, Spinello","Galli, Massimo"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222993","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25794","keywords":["Covid 19","complete genomes of SARS-CoV-2","phylogenetic analysis"],"source":"PubMed","locations":["ITALY","Italy","Lombardy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Mechanism"],"weight":1,"_version_":1662715354785251328,"score":107.08784},{"pmid":32222995,"title":"Phylogenetic analysis of the first four SARS-CoV-2 cases in Chile.","text":["Phylogenetic analysis of the first four SARS-CoV-2 cases in Chile.","The current pandemic caused by the new coronavirus is a worldwide public health concern. To aboard this emergency, and like never before, scientific groups around the world have been working in a fast and coordinated way in order to get the maximum of information about this virus when it has been almost three months since the first cases were detected in Wuhan province in China. The complete genome sequences of around 450 isolates are available, and studies about similarities and differences among them and with the close related viruses that caused similar epidemics in this century. In this work we studied the complete genome of the first four cases of the new coronavirus disease in Chile, from patients who traveled to Europe and Southeast Asia. Our findings reveal at least two different viral variants entries to Chilean territory, coming from Europe and Asia. We also sub-classified the isolates into variants according to punctual mutations in the genome. Our work contributes to the global information about transmission dynamics and the importance to take control measures to stop the spread of the infection. This article is protected by copyright. All rights reserved.","J Med Virol","Castillo, Andres E","Parra, Barbara","Tapia, Paz","Acevedo, Alejandra","Lagos, Jaime","Andrade, Winston","Arata, Loredana","Leal, Gabriel","Barra, Gisselle","Tambley, Carolina","Tognarelli, Javier","Bustos, Patricia","Ulloa, Soledad","Fasce, Rodrigo","Fernandez, Jorge","32222995"],"abstract":["The current pandemic caused by the new coronavirus is a worldwide public health concern. To aboard this emergency, and like never before, scientific groups around the world have been working in a fast and coordinated way in order to get the maximum of information about this virus when it has been almost three months since the first cases were detected in Wuhan province in China. The complete genome sequences of around 450 isolates are available, and studies about similarities and differences among them and with the close related viruses that caused similar epidemics in this century. In this work we studied the complete genome of the first four cases of the new coronavirus disease in Chile, from patients who traveled to Europe and Southeast Asia. Our findings reveal at least two different viral variants entries to Chilean territory, coming from Europe and Asia. We also sub-classified the isolates into variants according to punctual mutations in the genome. Our work contributes to the global information about transmission dynamics and the importance to take control measures to stop the spread of the infection. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Castillo, Andres E","Parra, Barbara","Tapia, Paz","Acevedo, Alejandra","Lagos, Jaime","Andrade, Winston","Arata, Loredana","Leal, Gabriel","Barra, Gisselle","Tambley, Carolina","Tognarelli, Javier","Bustos, Patricia","Ulloa, Soledad","Fasce, Rodrigo","Fernandez, Jorge"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222995","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25797","keywords":["COVID-19","Phylogeny","SARS-CoV-2"],"source":"PubMed","locations":["Wuhan","Chilean","Chile","China"],"countries":["Chile","China"],"countries_codes":["CHL|Chile","CHN|China"],"topics":["Transmission","Mechanism"],"weight":1,"_version_":1662715354811465729,"score":91.105675},{"pmid":32190908,"title":"A doubt of multiple introduction of SARS-CoV-2 in Italy: a preliminary overview.","text":["A doubt of multiple introduction of SARS-CoV-2 in Italy: a preliminary overview.","The emergence of the novel beta Coronavirus, recently renamed as severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, has raised serious concerns due to the virus rapid dissemination worldwide. Nevertheless, there is limited information about the genomic epidemiology of SARS-CoV-2 circulating in Italy from surveillance studies. The shortage of complete genomic sequences available impairs our understanding of the SARS-CoV-2 introduction and establishment in the country. To better understand its dynamics in Italy, we analysed complete genomes of SARS-CoV-2 isolates, obtained directly from clinical samples. Our phylogenetic reconstructions suggest possible multiple introduction of SARS-CoV-2. Continued genomic surveillance strategies are needed to improve monitoring and understanding of the currently SARS-CoV-2 epidemics, which might help to attenuate public health impact of infectious diseases. This article is protected by copyright. All rights reserved.","J Med Virol","Giovanetti, Marta","Angeletti, Silvia","Benvenuto, Domenico","Ciccozzi, Massimo","32190908"],"abstract":["The emergence of the novel beta Coronavirus, recently renamed as severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, has raised serious concerns due to the virus rapid dissemination worldwide. Nevertheless, there is limited information about the genomic epidemiology of SARS-CoV-2 circulating in Italy from surveillance studies. The shortage of complete genomic sequences available impairs our understanding of the SARS-CoV-2 introduction and establishment in the country. To better understand its dynamics in Italy, we analysed complete genomes of SARS-CoV-2 isolates, obtained directly from clinical samples. Our phylogenetic reconstructions suggest possible multiple introduction of SARS-CoV-2. Continued genomic surveillance strategies are needed to improve monitoring and understanding of the currently SARS-CoV-2 epidemics, which might help to attenuate public health impact of infectious diseases. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Giovanetti, Marta","Angeletti, Silvia","Benvenuto, Domenico","Ciccozzi, Massimo"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32190908","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25773","keywords":["COVID-2019","Italian outbreak","phylogenetic inference"],"source":"PubMed","locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Mechanism"],"weight":1,"_version_":1662334543464497152,"score":89.56645}]}